In the wake of health reform’s passage, Hospira Inc. will begin testing an experimental cheaper version of a popular anemia treatment in the first phase of a U.S. clinical trial.

A path for the Food and Drug Administration to approval “biosimilar” or biogeneric drugs was a part of health reform legislation passed by Congress and signed into law four months ago by President Barack Obama. Biotech brands are available only outside the U.S. but the law will enable biosimilars here in the coming years. Get the full story »